2025 Parkinson's Study Group Annual Meeting - San Diego
Streamline your trial design, improve data quality, and accelerate timelines so you can focus on what matters: advancing treatments for Parkinson’s disease.
At Koneksa Health, we empower neuroscience and Parkinson’s disease programs with remote, objective digital measurement solutions for faster, richer insight and more efficient trials.
Parkinson’s Risk Prediction
In partnership with the Michael J. Fox Foundation and Verily, we supported an initiative to detect early Parkinson’s risk using smartwatch-derived features
-
The dataset included 32 TB of smartwatch data -
(150,000 files from 350 participants).
-
Our team developed a composite machine learning predictor that effectively stratified individuals into high- and low-risk groups.
-
The resulting digital risk index predicted clinical test outcomes and supported identification of individuals at elevated risk for targeted intervention.
-
Our scaled compute allowed 10 - 20x faster delivery of extracted insights
Data Sources
Extracted Physiological Features
Activity
Gait
Vital Signs
Sleep
Integrated Machine Learning Model
Development of Risk Index
Risk is Associated with Clinical Severity
Our partnership with the Michael J. Fox Foundation
Koneksa is proud to partner with The Michael J. Fox Foundation (MJFF) in advancing the understanding of Parkinson's disease through rigorous science, innovative technology, and deep clinical expertise.
Together, we are harnessing high-quality wearable data, validated digital biomarkers, and machine-learning analytics to illuminate how Parkinson's progresses in the real world-bringing sharper, more sensitive measures into research and clinical trials.
Through MJFF-supported studies and access to landmark datasets like PPMI, this collaboration is accelerating the development of tools that can detect subtle changes, capture meaningful patient experiences, and ultimately bring better therapies to those living with Parkinson's.
Advancing patient-focused, data-rich, efficient trials that move neurodegenerative therapies from discovery to delivery
Koneksa transforms complex multimodal measurements into actionable clinical insights. Its platform unifies digital biomarkers, wearable sensor data, patient-reported outcomes, and clinical measures to deliver a deeper view of disease, treatment response, and patient well-being. With a remote-first, patient-centric approach, Koneksa reduces site burden, improves accessibility, and captures continuous real-world evidence. By accelerating trial timelines, enhancing decision-making, and supporting participant retention, Koneksa advances therapeutic innovation from early discovery through post-market studies.